Skip to main content

Table 3 Genetic variability of hepatitis B virus during occult infection.

From: Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy

Sequence information
Sample ID (HBV viral load) SL05/2001 (19 IU/ml)
Genotype (subtype) D (D1 - 97.95%1)
rt-HBV mutations: aa 79-255 3 N118H, Y135S, R153Q, N248H2
s-HBV mutations: aa 71-227 stop 3 R122K, P142LP, G145R, F179FS, V224AV2
Escape mutations 142L, 145R
Resistance prediction None4
Sample ID (HBV viral load) SL02/2010 (88,185 IU/ml)
Genotype (subtype) D (D1 - 98.23%1)
rt-HBV mutations: aa 43-330 3 N118H, Y135S, R153KQ, N248H2
s-HBV mutations: aa 35-227 stop 3 R122K, P142LP, D144DE, G145R, F179FS2
Escape mutations 142L, 144E, 145R
Resistance prediction None4
  1. 1 percent identity to the subtype as reported by HIV-GRADE_HBV-tool analysis (software available at http://www.hiv-grade.de/hbv_grade/deployed/grade.pl?program=hbvalg).
  2. 2 mutated residues are defined with respect to the HBV genotype D consensus sequence, residues in bold indicate changes involving both rt and s genes.
  3. 3 aa = amino acid; the range of sequenced amino acid residues covers the whole region of rt-HBV involved by antiviral resistance and the "a" determinant neutralizing antibody-binding domains of the s-HBV gene; aa numbered according to Stuyver et al [26].
  4. 4 the resistance prediction and reference sequence were assessed by HIV-GRADE_HBV-tool coupled with the interpretative algorithm Geno2Pheno [hbv] (available at http://hbv.bioinf.mpi-inf.mpg.de/index.php).